FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897850241> ?p ?o ?g. }

• W2897850241 endingPage "421" @default.
• W2897850241 startingPage "414" @default.
• W2897850241 abstract "Objective To investigate the prognostic value of the expressions of programmed cell death ligand 1 (PD-L1) and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy (NAC) for advanced high-grade serous ovarian cancer (HGSOC). Methods We collected pre- and post-NAC tumor samples from patients with advanced HGSOC between 2006 and 2017. Post-NAC tumor tissue samples were available for immunostaining from 131 patients. The expressions of PD-L1 and immune checkpoint markers were assessed by immunohistochemical staining and the status of tumor-infiltrating lymphocytes (TILs) was also evaluated. We examined whether there are significant associations between protein expression status and patient outcomes and whether significant changes in protein expression levels occurred in response to NAC. Results PD-L1 expression in the tumor cells was evaluated in 113 patients, 12 (10.6%) of whom had high PD-L1 expression (≥25%) in post-NAC tissues. However, these high levels were not associated with progression-free survival (PFS; P = 0.348) or overall survival (OS; P = 0.699). Similarly, high stromal TILs [≥50%; n = 16 (15.0%)] among the 107 patients evaluated did not show any significant impact on PFS (P = 0.250) or OS (P = 0.800). Moreover, an abundance of TILs (intraepithelial, CD8+, and Foxp3+) and the expression of immune checkpoint markers (PD-1, ICOS, and LAG-3) in residual tumors did not confer any significant survival benefit. The impact of NAC on PD-L1 expression and stromal TILs varied considerably among individual patients. Conclusion Although the expression of PD-L1 and immune checkpoint markers in residual tumors after NAC had no prognostic impact on survival in patients with HGSOC, post-NAC evaluation of these proteins in chemoresistant tumors may help select patients for immunotherapy trials." @default.
• W2897850241 created "2018-10-26" @default.
• W2897850241 creator A5010364211 @default.
• W2897850241 creator A5014854865 @default.
• W2897850241 creator A5027873499 @default.
• W2897850241 creator A5030649976 @default.
• W2897850241 creator A5036350381 @default.
• W2897850241 creator A5058355869 @default.
• W2897850241 creator A5069167592 @default.
• W2897850241 creator A5075088268 @default.
• W2897850241 date "2018-12-01" @default.
• W2897850241 modified "2023-10-17" @default.
• W2897850241 title "Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer" @default.
• W2897850241 cites W1985720566 @default.
• W2897850241 cites W2036905020 @default.
• W2897850241 cites W2106767659 @default.
• W2897850241 cites W2120431466 @default.
• W2897850241 cites W2136313650 @default.
• W2897850241 cites W2146967368 @default.
• W2897850241 cites W2147622445 @default.
• W2897850241 cites W2168893449 @default.
• W2897850241 cites W2169178790 @default.
• W2897850241 cites W2177804157 @default.
• W2897850241 cites W2186690436 @default.
• W2897850241 cites W2300386653 @default.
• W2897850241 cites W2438916529 @default.
• W2897850241 cites W2509217584 @default.
• W2897850241 cites W2515679040 @default.
• W2897850241 cites W2516784158 @default.
• W2897850241 cites W2552377883 @default.
• W2897850241 cites W2552487040 @default.
• W2897850241 cites W2584617802 @default.
• W2897850241 cites W2735354483 @default.
• W2897850241 cites W2753911561 @default.
• W2897850241 cites W2766806972 @default.
• W2897850241 cites W2772755698 @default.
• W2897850241 cites W2808811453 @default.
• W2897850241 doi "https://doi.org/10.1016/j.ygyno.2018.08.023" @default.
• W2897850241 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30314669" @default.
• W2897850241 hasPublicationYear "2018" @default.
• W2897850241 type Work @default.
• W2897850241 sameAs 2897850241 @default.
• W2897850241 citedByCount "29" @default.
• W2897850241 countsByYear W28978502412019 @default.
• W2897850241 countsByYear W28978502412020 @default.
• W2897850241 countsByYear W28978502412021 @default.
• W2897850241 countsByYear W28978502412022 @default.
• W2897850241 countsByYear W28978502412023 @default.
• W2897850241 crossrefType "journal-article" @default.
• W2897850241 hasAuthorship W2897850241A5010364211 @default.
• W2897850241 hasAuthorship W2897850241A5014854865 @default.
• W2897850241 hasAuthorship W2897850241A5027873499 @default.
• W2897850241 hasAuthorship W2897850241A5030649976 @default.
• W2897850241 hasAuthorship W2897850241A5036350381 @default.
• W2897850241 hasAuthorship W2897850241A5058355869 @default.
• W2897850241 hasAuthorship W2897850241A5069167592 @default.
• W2897850241 hasAuthorship W2897850241A5075088268 @default.
• W2897850241 hasConcept C121608353 @default.
• W2897850241 hasConcept C126322002 @default.
• W2897850241 hasConcept C143998085 @default.
• W2897850241 hasConcept C150173356 @default.
• W2897850241 hasConcept C167672396 @default.
• W2897850241 hasConcept C16930146 @default.
• W2897850241 hasConcept C203014093 @default.
• W2897850241 hasConcept C204232928 @default.
• W2897850241 hasConcept C2776694085 @default.
• W2897850241 hasConcept C2777701055 @default.
• W2897850241 hasConcept C2778326572 @default.
• W2897850241 hasConcept C2779727006 @default.
• W2897850241 hasConcept C2780427987 @default.
• W2897850241 hasConcept C2780851360 @default.
• W2897850241 hasConcept C502942594 @default.
• W2897850241 hasConcept C71924100 @default.
• W2897850241 hasConcept C8891405 @default.
• W2897850241 hasConceptScore W2897850241C121608353 @default.
• W2897850241 hasConceptScore W2897850241C126322002 @default.
• W2897850241 hasConceptScore W2897850241C143998085 @default.
• W2897850241 hasConceptScore W2897850241C150173356 @default.
• W2897850241 hasConceptScore W2897850241C167672396 @default.
• W2897850241 hasConceptScore W2897850241C16930146 @default.
• W2897850241 hasConceptScore W2897850241C203014093 @default.
• W2897850241 hasConceptScore W2897850241C204232928 @default.
• W2897850241 hasConceptScore W2897850241C2776694085 @default.
• W2897850241 hasConceptScore W2897850241C2777701055 @default.
• W2897850241 hasConceptScore W2897850241C2778326572 @default.
• W2897850241 hasConceptScore W2897850241C2779727006 @default.
• W2897850241 hasConceptScore W2897850241C2780427987 @default.
• W2897850241 hasConceptScore W2897850241C2780851360 @default.
• W2897850241 hasConceptScore W2897850241C502942594 @default.
• W2897850241 hasConceptScore W2897850241C71924100 @default.
• W2897850241 hasConceptScore W2897850241C8891405 @default.
• W2897850241 hasFunder F4320321408 @default.
• W2897850241 hasFunder F4320322030 @default.
• W2897850241 hasFunder F4320322120 @default.
• W2897850241 hasIssue "3" @default.
• W2897850241 hasLocation W28978502411 @default.
• W2897850241 hasLocation W28978502412 @default.
• W2897850241 hasOpenAccess W2897850241 @default.

• next